ALNY
Alnylam Pharmaceuticals, Inc.
$321.59
+8.55 (+2.73%)
At close · Jul 7
Market Cap
$42.65B
Shares
132,623,144
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$3.71B
+65.2%
FY2025
Net Income
$313.75M
+212.8%
FY2025
Gross Margin
81.77%
-4.6pp
FY2025
Operating Margin
13.51%
+21.4pp
FY2025
Diluted EPS
$2.33
+206.9%
FY2025
Operating Cash Flow
$524.08M
+6405.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $3.71B | $2.25B | $1.83B | $1.04B | $844.29M | $492.85M | $219.75M | $74.91M | $2.9M | $47.16M | — | — | — | — | — | $100.04M | $100.53M | $96.16M | |
| — | $677.17M | $306.51M | $268.22M | $140.17M | $115.01M | $74.19M | $25.06M | $1.8M | $0 | — | — | — | — | — | — | — | — | — | |
| — | $3.04B | $1.94B | $1.56B | $897.24M | $729.28M | $418.67M | $194.69M | $73.11M | $2.9M | — | — | — | — | — | — | — | — | — | |
| — | 81.77% | 86.37% | 85.33% | 86.49% | 86.38% | 84.95% | 88.6% | 97.59% | 100% | — | — | — | — | — | — | — | — | — | |
| — | $1.32B | $1.13B | $1B | $883.02M | $792.16M | $654.82M | $655.11M | $505.42M | $390.64M | $382.39M | $276.5M | $190.25M | $112.96M | $86.57M | $99.3M | $106.38M | $108.73M | $96.88M | |
| $272.23M | — | — | — | — | — | — | — | — | $199.37M | $89.35M | $60.61M | $44.53M | $27.15M | $44.61M | $38.28M | $37.73M | $39.91M | $27.12M | |
| — | $1.21B | $975.53M | $795.65M | $770.66M | $620.64M | $588.42M | $479.01M | $382.36M | $199.37M | $89.35M | — | — | — | — | — | — | — | — | |
| — | $55.66M | $56.67M | $54.05M | $44.47M | $47.57M | $34.77M | $17.18M | $15.25M | $13.37M | $15.13M | $19.05M | $11.93M | $10.23M | $9.04M | $5.13M | $4.94M | $5.99M | $5.73M | |
| $719.69M | — | — | — | — | — | — | — | — | $590M | $471.75M | $337.11M | $455.54M | $140.11M | $196.18M | $137.58M | $144.11M | $148.64M | $124M | |
| — | $3.21B | $2.43B | $2.11B | $1.82B | $1.55B | $1.32B | $1.16B | $889.58M | $590M | $471.75M | — | — | — | — | — | — | — | — | |
| — | $501.58M | -$176.89M | -$282.18M | -$785.07M | -$708.65M | -$828.44M | -$939.43M | -$814.67M | -$500.09M | -$424.59M | -$296.01M | -$404.98M | -$92.94M | -$129.46M | -$54.82M | -$44.07M | -$48.11M | -$27.84M | |
| — | 13.51% | -7.87% | -15.43% | -75.68% | -83.93% | -168.09% | -427.5% | -1087.56% | -17244.41% | -900.33% | — | — | — | — | — | -44.05% | -47.86% | -28.95% | |
| — | $557.24M | -$120.22M | -$228.12M | -$740.6M | -$661.09M | -$793.67M | -$922.26M | -$799.43M | -$486.72M | -$409.46M | -$276.96M | -$393.05M | -$82.71M | -$120.42M | -$49.69M | -$39.13M | -$42.12M | -$22.11M | |
| — | $252.63M | $141.86M | $121.22M | $155.97M | $143.02M | $84.5M | $0 | $0 | — | — | — | — | — | — | — | — | — | $872K | |
| — | $111.47M | $121.99M | $95.56M | $24.81M | $1.58M | $11.81M | $33.45M | $29.26M | — | — | — | — | — | $977K | $1.21M | $2.31M | $5.39M | $14.41M | |
| — | -$178.43M | -$200.49M | -$151.34M | -$341.92M | -$143.49M | -$27.16M | $54.18M | $54M | $9.21M | $14.48M | $5.94M | $4.38M | $1.02M | $12.87M | -$2.83M | $1.07M | $1.1M | $2.31M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$4.52M | -$3.51M | -$7.64M | -$4.91M | -$9.29M | |
| — | $323.15M | -$377.38M | -$433.52M | -$1.13B | -$852.14M | -$855.6M | -$885.25M | -$760.67M | -$490.87M | -$410.11M | -$290.07M | -$400.6M | -$91.92M | -$116.59M | -$57.65M | -$43M | -$47.01M | -$25.53M | |
| — | $9.41M | -$99.22M | $6.73M | $4.16M | $680K | $2.68M | $863K | $823K | $0 | $0 | $0 | -$40.21M | -$2.7M | -$10.57M | $0 | $514K | $582K | $719K | |
| — | $313.75M | -$278.16M | -$440.24M | -$1.13B | -$852.82M | -$858.28M | -$886.12M | -$761.5M | -$490.87M | -$410.11M | -$290.07M | -$360.4M | -$89.23M | -$106.01M | -$57.65M | -$43.52M | -$47.59M | -$26.25M | |
| — | 8.45% | -12.37% | -24.08% | -109.04% | -101.01% | -174.15% | -403.24% | -1016.58% | -16926.69% | -869.63% | — | — | — | — | — | -43.5% | -47.34% | -27.3% | |
| — | $328.17M | -$289.3M | -$418.96M | -$1.14B | -$842.46M | -$865.39M | -$889.42M | -$760.28M | -$491.87M | -$447.92M | -$334.47M | -$331.35M | -$85.17M | -$90.19M | -$58.53M | -$43.52M | -$48.06M | -$25.36M | |
| USD/shares | — | $2.39 | -$2.18 | -$3.52 | -$9.30 | -$7.20 | -$7.46 | -$8.11 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | $2.33 | -$2.18 | -$3.52 | -$9.30 | -$7.20 | -$7.46 | -$8.11 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 131M | 127.65M | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.6M | 83.99M | 74.28M | 61.55M | 50.29M | 42.41M | 42.04M | — | — |
| shares | — | 134.68M | 127.65M | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.6M | 83.99M | 74.28M | 61.55M | 50.29M | 42.41M | 42.04M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
138.02×
Biotechnology median 7.60×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Product | $2,986,549,000 | $1,646,228,000 | $1,241,474,000 | $894,329,000 | $662,138,000 | $361,520,000 | $166,537,000 | $12,535,000 |
| TTR | $2,486,625,000 | $1,223,307,000 | $912,384,000 | — | — | — | — | — |
| Amvuttra | $2,313,836,000 | $970,450,000 | $557,838,000 | $93,795,000 | $0 | $0 | — | — |
| Collaborations | $553,366,000 | $510,221,000 | $546,185,000 | $134,912,000 | $180,953,000 | — | — | — |
| Rare | $499,924,000 | $422,921,000 | $329,090,000 | — | — | — | — | — |
| GIVLAARI | $308,487,000 | $255,871,000 | $219,251,000 | $173,144,000 | $127,815,000 | $55,106,000 | $150,000 | $0 |
| OXLUMO | $191,437,000 | $167,050,000 | $109,839,000 | $69,782,000 | $59,586,000 | $333,000 | $0 | — |
| Royalty | $174,022,000 | $91,794,000 | $40,633,000 | $8,177,000 | $1,196,000 | $0 | $0 | — |
| ONPATTRO | $172,789,000 | $252,857,000 | $354,546,000 | $557,608,000 | $474,737,000 | $306,081,000 | $166,387,000 | $12,535,000 |
Key facts
CIK
1178670
CUSIP
02043Q107
13F (30d)
43 filings
21 filers
Visit website
Investor relations